On the other hand, secondary endpoints were a clinical response, safety, and toxicity to the combination therapy, along with levels of a marker for mCEA tumor and VEGF as a positive endogenous modulator of angiogenesis [176]. The gene discussed is VEGFA; the disease is neoplasm.